Optimal clinical trial design based on a dichotomous Markov-chain mixed-effect sleep model

Abstract D-optimal designs for discrete-type responses have been derived using generalized linear mixed models, simulation based methods and analytical approximations for computing the fisher information matrix (FIM) of non-linear mixed effect models with homogeneous probabilities over time. In this work, D-optimal designs using an analytical approximation of the FIM for a dichotomous, non-homogeneous, Markov-chain phase advanced sleep non-linear mixed effect model was investigated. The non-linear mixed effect model consisted of transition probabilities of dichotomous sleep data estimated as logistic functions using piecewise linear functions. Theoretical linear and nonlinear dose effects were added to the transition probabilities to modify the probability of being in either sleep stage. D-optimal designs were computed by determining an analytical approximation the FIM for each Markov component (one where the previous state was awake and another where the previous state was asleep). Each Markov component FIM was weighted either equally or by the average probability of response being awake or asleep over the night and summed to derive the total FIM (FIMtotal). The reference designs were placebo, 0.1, 1-, 6-, 10- and 20-mg dosing for a 2- to 6-way crossover study in six dosing groups. Optimized design variables were dose and number of subjects in each dose group. The designs were validated using stochastic simulation/re-estimation (SSE). Contrary to expectations, the predicted parameter uncertainty obtained via FIMtotal was larger than the uncertainty in parameter estimates computed by SSE. Nevertheless, the D-optimal designs decreased the uncertainty of parameter estimates relative to the reference designs. Additionally, the improvement for the D-optimal designs were more pronounced using SSE than predicted via FIMtotal. Through the use of an approximate analytic solution and weighting schemes, the FIMtotal for a non-homogeneous, dichotomous Markov-chain phase advanced sleep model was computed and provided more efficient trial designs and increased nonlinear mixed-effects modeling parameter precision.

[1]  M. Foracchia,et al.  POPED, a software for optimal experiment design in population kinetics , 2004, Comput. Methods Programs Biomed..

[2]  R. Larsen An introduction to mathematical statistics and its applications / Richard J. Larsen, Morris L. Marx , 1986 .

[3]  C. R. Rao,et al.  Information and the Accuracy Attainable in the Estimation of Statistical Parameters , 1992 .

[4]  Kristin E Karlsson Benefits of Pharmacometric Model-Based Design and Analysis of Clinical Trials , 2010 .

[5]  N. Breslow,et al.  Approximate inference in generalized linear mixed models , 1993 .

[6]  J. Wallin Dose Adaptation Based on Pharmacometric Models , 2009 .

[7]  Ss Beal,et al.  NONMEM User’s Guides. (1989–2009) , 2009 .

[8]  Meindert Danhof,et al.  A pharmacodynamic Markov mixed‐effect model for the effect of temazepam on sleep , 2000, Clinical pharmacology and therapeutics.

[9]  S. Ancoli-Israel,et al.  Characteristics of insomnia in the United States: results of the 1991 National Sleep Foundation Survey. I. , 1999, Sleep.

[10]  Ene I. Ette,et al.  Pharmacometrics : the science of quantitative pharmacology , 2007 .

[11]  Mats O. Karlsson,et al.  Modeling Sleep Data for a New Drug in Development using Markov Mixed-Effects Models , 2011, Pharmaceutical Research.

[12]  M K Stoller,et al.  Economic effects of insomnia. , 1994, Clinical therapeutics.

[13]  P. Lavie,et al.  Ultrashort sleep-waking schedule. III. 'Gates' and 'forbidden zones' for sleep. , 1986, Electroencephalography and clinical neurophysiology.

[14]  France Mentré,et al.  Development and implementation of the population Fisher information matrix for the evaluation of population pharmacokinetic designs , 2001, Comput. Methods Programs Biomed..

[15]  Derk-Jan Dijk,et al.  The selective extrasynaptic GABAA agonist, gaboxadol, improves traditional hypnotic efficacy measures and enhances slow wave activity in a model of transient insomnia. , 2006, Sleep.

[16]  T. Harada,et al.  Effects of meal habits and alcohol/cigarette consumption on morningness-eveningness preference and sleep habits by Japanese female students aged 18-29. , 2009, Journal of physiological anthropology.

[17]  H. Cramér Mathematical methods of statistics , 1947 .

[18]  M. Pfister,et al.  The Emerging Scientific Discipline of Pharmacometrics , 2010, Journal of clinical pharmacology.

[19]  Lewis B. Sheiner,et al.  Estimation of population characteristics of pharmacokinetic parameters from routine clinical data , 1977, Journal of Pharmacokinetics and Biopharmaceutics.

[20]  Andrew C. Hooker,et al.  PopED: An extended, parallelized, nonlinear mixed effects models optimal design tool , 2012, Comput. Methods Programs Biomed..

[21]  Alain Mallet,et al.  Optimal design in random-effects regression models , 1997 .

[22]  J. Walsh,et al.  The direct economic costs of insomnia in the United States for 1995. , 1999, Sleep.

[23]  Matt P. Wand,et al.  Fisher information for generalised linear mixed models , 2007 .

[24]  Giuseppe De Nicolao,et al.  Multinomial logistic estimation of Markov-chain models for modeling sleep architecture in primary insomnia patients , 2010, Journal of Pharmacokinetics and Pharmacodynamics.

[25]  L. Aarons,et al.  Population Fisher information matrix and optimal design of discrete data responses in population pharmacodynamic experiments , 2009, Journal of Pharmacokinetics and Pharmacodynamics.

[26]  L Aarons,et al.  Population pharmacokinetics. , 1992, International journal of clinical pharmacology, therapy, and toxicology.

[27]  A. Krause,et al.  Pharmacometrics: The Science of Quantitative Pharmacology , 2008 .

[28]  Junshui Ma,et al.  EEG power spectra response to a 4-h phase advance and gaboxadol treatment in 822 men and women. , 2011, Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine.

[29]  B Kemp,et al.  Simulation of human hypnograms using a Markov chain model. , 1986, Sleep.

[30]  Mats O. Karlsson,et al.  Performance in population models for count data, part I: maximum likelihood approximations , 2009, Journal of Pharmacokinetics and Pharmacodynamics.

[31]  Giuseppe De Nicolao,et al.  Multinomial Logistic Functions in Markov Chain Models of Sleep Architecture: Internal and External Validation and Covariate Analysis , 2011, The AAPS Journal.

[32]  L Aarons,et al.  Population pharmacokinetics: theory and practice. , 1991, British journal of clinical pharmacology.

[33]  G. Simon,et al.  Prevalence, burden, and treatment of insomnia in primary care. , 1997, The American journal of psychiatry.